4
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
FDA Denies Approval for Lung Cancer Drug Developed in China
The FDA has denied approval for ivonescimab, a lung cancer treatment developed by Summit Therapeutics. The drug was created in China and aimed at entering the U.S. market.
Companies
Summit Therapeutics
Our neutral summary
The FDA has denied approval for ivonescimab, a lung cancer treatment developed by Summit Therapeutics. The drug was created in China and aimed at entering the U.S. market.
Read the full story at New York Times — Politics ↗
The reporting belongs to
New York Times — Politics;
we don't reproduce it.